Therapeutic Agent for Improvement of Wound Healing
- Summary
- Wound healing involves a series of integrated physiological processes, which are fragile and susceptible to interruption or failure leading to the formation of chronic non-healing wounds. Complete healing rates for diabetic foot ulcers, venous leg ulcers or pressure ulcers remain low and therefore new strategies in wound care that could facilitate wound retraction and closure are needed.
伤口愈合涉及一系列综合生理过程，这些生理过程比较脆弱，很容易中断或无法完成，导致伤口长期不愈。糖尿病足部溃疡、静脉性溃疡或压迫溃疡的完全愈合速度很慢，因此需要新的伤口护理策略，促进伤口的收缩和闭合。
The present invention describes a novel protein that is shown to function during development as well as in wound repair. This protein represents a new therapeutic target for modulating the wound repair process. This protein at the wound site leads to a decrease in normal wound retraction and closure duration in animal models, effectively reducing the healing time.
本发明涉及一种新的蛋白质，经证明，该蛋白质能促进发育和创面修复。这种蛋白质提供了调节创面修复过程的新的治疗靶点。在动物模型的创面部位使用这种蛋白质能使伤口的收缩和闭合期限短于一般期限，有效缩短愈合时间。
Validated in rodent models of wound healing
已用啮齿类动物模型验证伤口愈合
Provides a novel approach in advanced wound management
提供先进的新型伤口护理方法
Potential clinical applications of this novel technology include tissue remodeling
新技术的潜在临床应用包括组织重构
Can be used to address other healing pathologies such as fibrosis, scar tissues, and diabetic ulcers
可用于解决纤维化、结痂组织和糖尿病溃疡等其他愈合病变问题
- Technology Application
- 其它
- Detailed Technology Description
- Early stage
早期阶段
- Type of Cooperation
- 技术售让
- Coverage Areas
- 生物技术/制药/医疗
- Goods and Services
- 制药行业
For more information, please click Here
